Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC

NCT06096038 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer
Relapse
Recurrent
Refractory Cancer

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
BIOLOGICAL: Cell Therapy

Sponsor

UNC Lineberger Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]